CoChat
Sign Up
Cited by 4Alzheimer's disease research and treatmentsPluripotent Stem Cells ResearchNeurogenesis and neuroplasticity mechanisms

Direct conversion of fibroblast into neurons for Alzheimer's disease research: a systematic review

Open access
Sattarov, Roman, Toresson, Håkan, Orbjörn, Camilla, Mattsson-Carlgren, Niklas·2023·Journal of Alzheimer’s Disease
DOI 10.3233/jad-230119PMC PMC10578293
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder without a cure. Innovative disease models, such as induced neurons (iNs), could enhance our understanding of AD mechanisms and accelerate treatment development. However, a review of AD human iN studies is necessary to consolidate knowledge. Objective: The objective of this review is to examine the current body of literature on AD human iN cells and provide an overview of the findings to date. Methods: We searched two databases for relevant studies published between 2010 and 2023, identifying nine studies meeting our criteria. Results: Reviewed studies indicate the feasibility of generating iNs directly from AD patients’ fibroblasts using chemical induction or viral vectors. These cells express mature neuronal markers, including MAP-2, NeuN, synapsin, and tau. However, most studies were limited in sample size and primarily focused on autosomal dominant familial AD (FAD) rather than the more common sporadic forms of AD. Several studies indicated that iNs derived from FAD fibroblasts exhibited abnormal amyloid-β metabolism, a characteristic feature of AD in humans. Additionally, elevated levels of hyperphosphorylated tau, another hallmark of AD, were reported in some studies. Conclusion: Although only a limited number of small-scale studies are currently available, AD patient-derived iNs hold promise as a valuable model for investigating AD pathogenesis. Future research should aim to conduct larger studies, particularly focusing on sporadic AD cases, to enhance the clinical relevance of the findings for the broader AD patient population. Moreover, these cells can be utilized in screening potential novel treatments for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-230119

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Detecting the expression of Map-2 and NeuN helps determine the extent of neuronal damage and degeneration.

    “Map-2 and NeuN are the neuronal marker proteins used to assess the morphology and function of neurons, and detecting the expression of Map-2 and NeuN could help know the extent of neuronal damage and degeneration in the present study (Götz and Ittner, 2008; Ghatak et al., 2019; Sattarov et al., 2023).”

    From AD-Like Neuropsychiatric Dysfunction in a Mice Model Induced by a Combination of High-Fat Diet and Intraperitoneal Injection of Streptozotocin (2024) · cites this paper as Sattarov et al., 2023

    The Results table lists MAP-2 and NeuN as markers of induced neurons. The Discussion (AD-related features in iN cells) reports that fewer MAP2-positive cells under APP overexpression may suggest decreased cell survival. It does not establish that measuring MAP-2 and NeuN together determines the extent of neuronal damage or degeneration; page numbers are unavailable in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 84

  1. [2]Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer’s disease. Lancet 397, 1577– 1590. 33667416 PMC8354300
  2. [3]Insel PS, Hansson O, Mattsson-Carlgren N (2021) Association between Apolipoprotein E ɛ2 vs ɛ4, age, and β-amyloid in adults without cognitive impairment. JAMA Neurol 78, 229– 235. 33044487 PMC7551211
  3. [4]Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189. 22229116 PMC3234452
  4. [5]Mantzavinos V, Alexiou A (2017) Biomarkers for Alzheimer’s disease diagnosis. Curr Alzheimer Res 14, 1149– 1154. 28164766 PMC5684784
  5. [6]Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O (2017) Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 8, 1214. 29089479 PMC5663717
  6. [7]Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 25, 5789. 33302541 PMC7764106
  7. [8]Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2, a006296. 23028126 PMC3475404
  8. [9]Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298, 789– 791. 12399581
  9. [10]Troutwine BR, Hamid L, Lysaker CR, Strope TA, Wilkins HM (2021) Apolipoprotein E and Alzheimer’s disease. Acta Pharm Sin B 12, 496– 510. 35256931 PMC8897057
  10. [11]Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 322– 333. 24450891 PMC4159618
  11. [12]Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 311– 321. 24450890
  12. [14]Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM (2021) Donanemab in early Alzheimer’s disease. N Engl J Med 384, 1691– 1704. 33720637
  13. [15]Tampi RR, Forester BP, Agronin M (2021) Aducanumab: Evidence from clinical trial data and controversies. Drugs Context 10, 2021-7– 3. PMC8491638 34650610
  14. [16]van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388, 9– 21. 36449413
  15. [17]Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C (2002) Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res 956, 36– 44. 12426044
  16. [18]Krezymon A, Richetin K, Halley H, Roybon L, Lassalle JM, Francès B, Verret L, Rampon C (2013) Modifications of hippocampal circuits and early disruption of adult neurogenesis in the Tg2576 mouse model of Alzheimer’s disease. PLoS One 8, e76497. 24086745 PMC3785457
  17. [19]Li X, Bao X, Wang R (2016) Experimental models of Alzheimer’s disease for deciphering the pathogenesis and therapeutic screening (Review). Int J Mol Med 37, 271– 283. 26676932
  18. [20]Götz J, Bodea LG, Goedert M (2018) Rodent models for Alzheimer disease. Nat Rev Neurosci 19, 583– 598. 30194347
  19. [21]Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD (2022) Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s disease: A comprehensive review. Health Psychol Res 10, 31925. 35928986 PMC9346954
  20. [24]Livesey FJ (2014) Human stem cell models of dementia. Hum Mol Genet 23, 35– 39. PMC4170721 24939911
  21. [25]LaFerla FM, Green KN (2012) Animal models of Alzheimer disease. Cold Spring Harb Perspect Med 2, a006320. 23002015 PMC3543097
  22. [26]Bliss LA, Sams MR, Deep-Soboslay A, Ren-Patterson R, Jaffe AE, Chenoweth JG, Jaishankar A, Kleinman JE, Hyde TM (2012) Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PLoS One 7, e45282. 23028905 PMC3459947
  23. [27]Rose SE, Frankowski H, Knupp A, Berry BJ, Martinez R, Dinh SQ, Bruner LT, Willis SL, Crane PK, Larson EB, Grabowski T, Darvas M, Dirk Keene C, Young JE (2018) Leptomeninges-derived induced pluripotent stem cells and directly converted neurons from autopsy cases with varying neuropathologic backgrounds. J Neuropathol Exp Neurol 77, 353– 360. 29474672 PMC6018913
  24. [28]Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663– 676. 16904174
  25. [29]Chang CY, Ting HC, Liu CA, Su HL, Chiou TW, Lin SZ, Harn HJ, Ho TJ (2020) Induced pluripotent stem cell (iPSC)-based neurodegenerative disease models for phenotype recapitulation and drug screening. Molecules 25, 2000. 32344649 PMC7221979
  26. [30]Amponsah AE, Guo R, Kong D, Feng B, He J, Zhang W, Liu X, Du X, Ma Z, Liu B, Ma J, Cui H (2021) Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease. Rev Neurosci 32, 379– 402. 33550785
  27. [31]Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LNP, Walsh DM, Selkoe DJ, Young-Pearse TL (2014) The familial Alzheimer’s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Genet 23, 3523– 3536. 24524897 PMC4049307
  28. [34]Ko HJ, Chiou SJ, Wong YH, Wang YH, Lai YL, Chou CH, Wang C, Loh JK, Lieu AS, Cheng JT, Lin Y Te, Lu PJ, Fann MJ, Huang CY, Hong YR (2019) GSKIP-mediated anchoring increases phosphorylation of tau by PKA but not by GSK3beta via cAMP/PKA/GSKIP/GSK3/Tau axis signaling in cerebrospinal fluid and iPS cells in Alzheimer disease. J Clin Med 8, 1751. 31640277 PMC6832502
  29. [35]Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W, Gao L, Shen L, Huang Y, Xie G, Zhao H, Jin Y, Tang B, Yu Y, Zhao J, Pei G (2015) Direct conversion of normal and Alzheimer’s disease human fibroblasts into neuronal cells by small molecules. Cell Stem Cell 17, 204– 212. 26253202
  30. [37]Preman P, Tcw J, Calafate S, Snellinx A, Alfonso-Triguero M, Corthout N, Munck S, Thal DR, Goate AM, De Strooper B, Arranz AM (2021) Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques. Mol Neurodegener 16, 68. 34563212 PMC8467145
  31. [38]Armijo E, Edwards G, Flores A, Vera J, Shahnawaz M, Moda F, Gonzalez C, Sanhueza M, Soto C (2021) Induced pluripotent stem cell-derived neural precursors improve memory, synaptic and pathological abnormalities in a mouse model of Alzheimer’s disease. Cells 10, 1802. 34359972 PMC8303262
  32. [39]Liu XY, Yang LP, Zhao L (2020) Stem cell therapy for Alzheimer’s disease. World J Stem Cells 12, 787– 802. 32952859 PMC7477654
  33. [40]Ravaioli F, Bacalini MG, Franceschi C, Garagnani P (2018) Age-related epigenetic derangement upon reprogramming and differentiation of cells from the elderly. Genes (Basel) 9, 39. 29337900 PMC5793190
  34. [41]Pfisterer U, Kirkeby A, Torper O, Wood J, Nelander J, Dufour A, Björklund A, Lindvall O, Jakobsson J, Parmar M (2011) Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A 108, 10343– 10348. 21646515 PMC3121829
  35. [43]Victor MB, Richner M, Olsen HE, Lee SW, Monteys AM, Ma C, Huh CJ, Zhang B, Davidson BL, Yang XW, Yoo AS (2018) Striatal neurons directly converted from Huntington’s disease patient fibroblasts recapitulate age-associated disease phenotypes. Nat Neurosci 21, 341– 352. 29403030 PMC5857213
  36. [45]Yokoyama AS, Rutledge JC, Medici V (2017) DNA methylation alterations in Alzheimer’s disease. Environ Epigenetics 3, dvx008. PMC5804548 29492310
  37. [46]Bennett DA, Yu L, Yang J, Srivastava GP, Aubin C, De Jager PL (2015) Epigenomics of Alzheimer’s disease. Transl Res 165, 200– 220. 24905038 PMC4233194
  38. [47]Phipps AJ, Vickers JC, Taberlay PC, Woodhouse A (2016) Neurofilament-labeled pyramidal neurons and astrocytes are deficient in DNA methylation marks in Alzheimer’s disease. Neurobiol Aging 45, 30– 42. 27459923
  39. [50]Lord J, Cruchaga C (2014) The epigenetic landscape of Alzheimer’s disease. Nat Neurosci 17, 1138– 1140. 25157507 PMC5472058
  40. [51]Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28, 1057– 1068. 20944598
  41. [52]Poon CH, Tse LSR, Lim LW (2020) DNA methylation in the pathology of Alzheimer’s disease: From gene to cognition. Ann N Y Acad Sci 1475, 15– 33. 32491215
  42. [53]Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y, Dwork AJ, Schultz MD, Yu M, Tonti-Filippini J, Heyn H, Hu S, Wu JC, Rao A, Esteller M, He C, Haghighi FG, Sejnowski TJ, Behrens MM, Ecker JR (2013) Global epigenomic reconfiguration during mammalian brain development. Science 341, 517– 525. PMC3785061 23828890
  43. [54]Yang N, Ng YH, Pang ZP, Südhof TC, Wernig M (2011) Induced neuronal cells: How to make and define a neuron. Cell Stem Cell 9, 517– 525. 22136927 PMC4377331
  44. [55]Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M (2010) Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035– 1041. 20107439 PMC2829121
  45. [57]Cheng F, Fransson LÅ, Mani K (2021) Reversal of apolipoprotein E4-dependent or chemical-induced accumulation of APP degradation products by vitamin C-induced release of heparan sulfate from glypican-1. Glycobiology 31, 800– 811. 33403386
  46. [58]Ma S, Zang T, Liu ML, Zhang CL (2020) Aging-relevant human basal forebrain cholinergic neurons as a cell model for Alzheimer’s disease. Mol Neurodegener 15, 61. 33087140 PMC7579825
  47. [59]Drouin-Ouellet J, Lau S, Brattås PL, Rylander Ottosson D, Pircs K, Grassi DA, Collins LM, Vuono R, Andersson Sjöland A, Westergren-Thorsson G, Graff C, Minthon L, Toresson H, Barker RA, Jakobsson J, Parmar M (2017) REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. EMBO Mol Med 9, 1117– 1131. 28646119 PMC5538296
  48. [60]Kim J, Kim H, Yoo J, Shin J, Chang Y, Jung J, Jo DG, Kim J, Jang W, Lengner CJ, Kim BS (2017) Modelling APOE ɛ3/4 allele-associated sporadic Alzheimer’s disease in an induced neuron. Brain 140, 2193– 2209. 28899010
  49. [61]Kim H, Kim S, Cho B, Shin J, Kim J (2022) APOE ɛ4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease. Transl Neurodegener 11, 45. 36284363 PMC9594913
  50. [66]Hallengren J, Chen PC, Wilson SM (2013) Neuronal ubiquitin homeostasis. Cell Biochem Biophys 67, 67– 73. 23686613 PMC3758786
  51. [67]Traxler L, Edenhofer F, Mertens J (2019) Next-generation disease modeling with direct conversion: A new path to old neurons. FEBS Lett 593, 3316– 3337. 31715002 PMC6907729
  52. [68]Das AT, Tenenbaum L, Berkhout B (2016) Tet-on systems for doxycyckine-inducible gene expression. Curr Gene Ther 16, 156– 167. 27216914 PMC5070417
  53. [69]Liu M-L, Zang T, Zou Y, Chang JC, Gibson JR, Huber KM, Zhang C-L (2013) Small molecules enable neurogenin 2 to efficiently convert human fibroblasts into cholinergic neurons. Nat Commun 4, 2183. 23873306 PMC3843951
  54. [70]Zhou C, Yang G, Chen M, He L, Xiang L, Ricupero C, Mao JJ, Ling AJ (2015) Lhx6 and Lhx8: Cell fate regulators and beyond. FASEB J 29, 4083– 4091. 26148970 PMC4566936
  55. [71]Buckley DM, Burroughs-Garcia J, Kriks S, Lewandoski M, Waters ST (2020) Gbx1 and Gbx2 are essential for normal patterning and development of interneurons and motor neurons in the embryonic spinal cord. J Dev Biol 8, 9. 32244588 PMC7345146
  56. [72]Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, Südhof TC, Wernig M (2011) Induction of human neuronal cells by defined transcription factors. Nature 476, 220– 223. 21617644 PMC3159048
  57. [73]Mollinari C, Merlo D (2021) Direct reprogramming of somatic cells to neurons: Pros and cons of chemical approach. Neurochem Res 46, 1330– 1336. 33666839 PMC8084785
  58. [74]Vasan L, Park E, David LA, Fleming T, Schuurmans C (2021) Direct neuronal reprogramming: Bridging the gap between basic science and clinical application. Front Cell Dev Biol 9, 681087. 34291049 PMC8287587
  59. [75]Gascón S, Masserdotti G, Russo GL, Götz M (2017) Direct neuronal reprogramming: Achievements, hurdles, and new roads to success. Cell Stem Cell 21, 18– 34. 28686866
  60. [76]Ladewig J, Mertens J, Kesavan J, Doerr J, Poppe D, Glaue F, Herms S, Wernet P, Kögler G, Müller FJ, Koch P, Brüstle O (2012) Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat Methods 9, 575– 578. 22484851
  61. [77]Yang Y, Chen R, Wu X, Zhao Y, Fan Y, Xiao Z, Han J, Sun L, Wang X, Dai J (2019) Rapid and efficient conversion of human fibroblasts into functional neurons by small molecules. Stem Cell Rep 13, 862– 876. PMC6893066 31631018
  62. [78]Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, Larson GA, He Y, Huang Q, Tan AC, Zhang D, Benke TA, Sladek JR, Zahniser NR, Li CY (2012) Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res 22, 321– 332. 22105488 PMC3271588
  63. [79]Curtis A (2004) Tutorial on the biology of nanotopography. IEEE Trans Nanobioscience 3, 293– 295. 15631141
  64. [81]Hasirci V, Pepe-Mooney BJ (2012) Understanding the cell behavior on nano-/micro-patterned surfaces. Nanomedicine (Lond) 7, 1375– 1389. 22812706
  65. [82]Ghibaudo M, Trichet L, Le Digabel J, Richert A, Hersen P, Ladoux B (2009) Substrate topography induces a crossover from 2D to 3D behavior in fibroblast migration. Biophys J 97, 357– 368. 19580774 PMC2711370
  66. [83]Colasante G, Rubio A, Massimino L, Broccoli V (2019) Direct neuronal reprogramming reveals unknown functions for known transcription factors. Front Neurosci 13, 283. 30971887 PMC6445133
  67. [84]Fode C, Ma Q, Casarosa S, Ang S-L, Anderson DJ, Ois Guillemot F (2000) A role for neural determination genes in specifying the dorsoventral identity of telencephalic neurons. Genes Dev 14, 67– 80. 10640277 PMC316337
  68. [85]Chanda S, Ang CE, Davila J, Pak C, Mall M, Lee QY, Ahlenius H, Jung SW, Südhof TC, Wernig M (2014) Generation of induced neuronal cells by the single reprogramming factor ASCL1. Stem Cell Reports 3, 282– 296. 25254342 PMC4176533
  69. [86]Ambasudhan R, Talantova M, Coleman R, Yuan X, Zhu S, Lipton SA, Ding S (2011) Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 9, 113– 118. 21802386 PMC4567246
  70. [87]Zhang L, Yin JC, Yeh H, Ma NX, Lee G, Chen XA, Wang Y, Lin L, Chen L, Jin P, Wu GY, Chen G (2015) Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell 17, 735– 747. 26481520 PMC4675726
  71. [88]Esposito M, Sherr GL (2019) Epigenetic modifications in Alzheimer’s neuropathology and therapeutics. Front Neurosci 13, 476. 31133796 PMC6524410
  72. [89]Eid A, Bihaqi SW, Hemme C, Gaspar JM, Hart RP, Zawia NH (2018) Histone acetylation maps in aged mice developmentally exposed to lead: Epigenetic drift and Alzheimer-related genes. Epigenomics 10, 573– 583. 29722544 PMC5992572
  73. [90]Gasparoni G, Bultmann S, Lutsik P, Kraus TFJ, Sordon S, Vlcek J, Dietinger V, Steinmaurer M, Haider M, Mulholland CB, Arzberger T, Roeber S, Riemenschneider M, Kretzschmar HA, Giese A, Leonhardt H, Walter J (2018) DNA methylation analysis on purified neurons and glia dissects age and Alzheimer’s disease-specific changes in the human cortex. Epigenetics Chromatin 11, 41. 30045751 PMC6058387
  74. [91]Mattsson N, Lönneborg A, Boccardi M, Blennow K, Hansson O (2017) Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging 52, 196– 213. 28317649
  75. [92]Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O (2019) Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol 76, 1060– 1069. 31233127 PMC6593637
  76. [93]van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM (2006) Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: A prospective case-cohort study. Lancet Neurol 5, 655– 660. 16857570
  77. [94]Hanson AJ, Prasad JE, Nahreini P, Andreatta C, Kumar B, Yan XD, Prasad KN (2003) Overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide, and nitric oxide) in differentiated neuroblastoma cells. J Neurosci Res 74, 148– 159. 13130517
  78. [95]Brewer GJ, Herrera RA, Philipp S, Sosna J, Reyes-Ruiz JM, Glabe CG (2020) Age-related intraneuronal aggregation of amyloid-β in endosomes, mitochondria, autophagosomes, and lysosomes. J Alzheimers Dis 73, 229– 246. 31771065 PMC7029321
  79. [96]Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367, 795– 804. 22784036 PMC3474597
  80. [97]Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R, Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772. 32722745 PMC7388060
  81. [98]D’Avanzo C, Aronson J, Kim YH, Choi SH, Tanzi RE, Kim DY (2015) Alzheimer’s in 3D culture: Challenges and perspectives. BioEssays 37, 1139– 1148. 26252541 PMC4674791
  82. [99]Zhang D, Pekkanen-Mattila M, Shahsavani M, Falk A, Teixeira AI, Herland A (2014) A 3D Alzheimer’s disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. Biomaterials 35, 1420– 1428. 24290439
  83. [100]Slanzi A, Iannoto G, Rossi B, Zenaro E, Constantin G (2020) In vitro models of neurodegenerative diseases. Front Cell Dev Biol 8, 1420– 1428. PMC7247860 32528949
  84. [101]Liu X, Huang J, Chen T, Wang Y, Xin S, Li J, Pei G, Kang J (2008) Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. Cell Res 18, 1177– 1189. 19030024

Cited by

Sorted by citations

Authors
Sattarov, R., Toresson, H., Orbjörn, C., & Mattsson-Carlgren, N.
Affiliations
  • Lund University (SE)
  • Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, Lund, Sweden
Corresponding author
Sattarov, Roman
ORCID
Sattarov, Roman
Venue
Journal of Alzheimer’s Disease
Publisher
SAGE Publications
Published
2023-08-25
Volume
95
Issue
3
Pages
805-828
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
DOI
10.3233/jad-230119
PMC
PMC10578293
OpenAlex
W4386245235
Cited by
4
References
15
Citations by year
2025: 3 · 2024: 1
FWCI
0.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Australian Government
  • Lunds Universitet
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Sveriges Läkarförbund
  • Skånes universitetssjukhus
  • Marcus och Amalia Wallenbergs minnesfond
  • Stiftelsen Bundy Academy
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
Alzheimer's disease, induced neurons
MeSH terms
Alzheimer Disease, Fibroblasts, Humans, Neurons, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review